- $1.10bn
- $1.09bn
- $157.78m
Director/PDMR Shareholding
Brief: Biopharma Credit Says It Is In Best Interest Of Co To Update Discount Control Mechanism
UPDATES TO THE DISCOUNT CONTROL MECHANISM
FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Director/PDMR Shareholding
Brief: Biopharma Credit Announces Interim Dividend For Financial Period Ending 31 Mar Of $0.0175 Per Ordinary Share
UPDATE ON INVESTMENT
Notice of Full Year Results
STATEMENT RE IMMUNOGEN, INC.
Europe Research Roundup: Morphosys, Renishaw, Verallia
STATEMENT RE COHERUS BIOSCIENCES, INC.
Director/PDMR Shareholding
UPDATE ON INVESTMENT
UPDATE ON INVESTMENT
PUBLICATION OF CIRCULAR AND NOTICE OF GM
STATEMENT RE IMMUNOGEN, INC.
UPDATE ON INVESTMENT
UPDATE ON INVESTMENT
UPDATE ON INVESTMENT